Development of a discovery platform based on microfluidics and fluorescent cell f

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$695,816.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK092122-01
Award Id:
n/a
Agency Tracking Number:
R43DK092122
Solicitation Year:
2011
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA08-114
Small Business Information
One Broadway, 14th Floor, Cambridge, MA, 02142
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
962790569
Principal Investigator:
MURALIKRISHNA VEMULA
(617) 871-9782
mvemula@nivarta.com
Business Contact:
MURALIKRISHNA VEMULA
(617) 871-9782
mvemula@nivarta.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): The overall goal of the project is to develop discovery platform based on microfluidics and functional cell assays that is suitable for screening hundreds of proteins or small-molecule compounds simultaneously in a cost-effective and high throughput manner. The projects Specific Aims are: (1) To develop a microfluidic-based platform for high-throughput screening of potential protein and small molecule therapeutics. (2) To develop an insulin stimulated glucose uptake assay in differentiated 3T3-L1 adipocytes using fluorescent 2-deoxy glucose (2-DOG) analog. (3) To integrate and perform a functional 2-DOG uptake assay in the microfluidics based multi-well cell culture biochip. The deliverable from this completed project isa cost-effective microfluidics based platform suitable for high throughput screening of proteins and small molecule therapeutic compounds. PUBLIC HEALTH RELEVANCE: The long term objective of the project is to identify protein and small molecule therapeutics to treat diseases such as diabetes, obesity, cancer and neurological disorders. As a first step towards this objective, a platform based on microfluidics technology and functional cell bioassays is being developed to screen the entire human proteome and small molecule libraries in a cost-effective and time saving manner. Presently, safety and efficacy of most of the drugs in the market is still a primary concern. However, with more therapies becoming available, it is possible that not only safety standards will be met but also the cost of drugs will be lowered.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government